The timing on the Myring generic is only a delay. From my viewpoint it is glass half full. The important point here is that it is not a rejection. I am very hopeful this will be resolved in a timely manner and MYX can get on with bringing this new generic to market.
The mid point review for Nextstellis is very encouraging especially considering the size of the prize as this drug is going to provide a new option for women in a huge market. There is a similar process under way in Canada with Mithra's on ground partner there.
Cheers................Daicosisgod
Ann: Mayne Pharma provides update on Women's Health pipeline, page-5
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$5.08 |
Change
0.010(0.20%) |
Mkt cap ! $412.7M | |||
| Open | High | Low | Value | Volume |
| $5.13 | $5.15 | $5.08 | $445.2K | 87.01K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 810 | $5.08 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.15 | 2033 | 2 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| MYX (ASX) Chart |